Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fevipiprant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fevipiprant SCHEMBL29355753 | 1.00 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1939556 | 0.92 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL21591931 | 0.90 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL1940778 | 0.90 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL20508235 | 0.90 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL21913709 | 0.89 | PTGDR2 (0.80) | PTGDR2 | |
| SCHEMBL1940435 | 0.88 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1941189 | 0.87 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1941253 | 0.87 | PTGDR2 (0.82) | PTGDR2 | |
| SCHEMBL28356397 | 0.87 | PTGDR2 (0.76) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259656-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-08-18 | — | — | US | claimed |
| EP-3337803-B1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3941579-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | Amerimmune, LLC (US) | 2022-01-26 | — | — | EP | claimed |
| CN-107849041-B | Genetic markers associated with response to CRTH2 receptor antagonists | 默沙东公司 | 2021-07-23 | — | — | CN | claimed |
| CN-108137503-B | Process for the preparation of 1- (4-methanesulfonyl-2-trifluoromethyl-benzyl) -2-methyl-1H-pyrrolo [2,3-B ] pyridin-3-yl-acetic acid | 诺华股份有限公司 | 2021-06-15 | — | — | CN | claimed |
| WO-2020226936-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-12 | — | — | WO | claimed |
| WO-2020190905-A1 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND CRTH2 | AMERIMMUNE, LLC (US) | 2020-09-24 | — | — | WO | claimed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | claimed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | claimed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | claimed |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2018-09-27 | — | — | US | claimed |
| US-20180237856-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | claimed |
| EP-3337803-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-27 | — | — | EP | claimed |
| WO-2017015418-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-01-26 | — | — | WO | claimed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | claimed |
| US-8470848-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-06-25 | — | — | US | claimed |
| EP-1761529-B3 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | claimed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | claimed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | claimed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | disclosed |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | BioAlta, LLC | 2024-10-17 | — | — | US | disclosed |
| EP-4424322-A2 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | Novartis AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | disclosed |
| EP-4245376-A2 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | Novartis AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-3206711-B1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | NOVARTIS AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| EP-3328500-B1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-114920840-A | Antibody molecules against PD-L1 and uses thereof | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220259656-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3337803-B1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-05-05 | — | — | US | disclosed |
| CN-114272371-A | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3489233-B1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| CN-107001478-B | Antibody molecules against PD-L1 and uses thereof | 诺华股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-108025051-B | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210284737-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | NOVARTIS AG (CH) | 2021-09-16 | — | — | US | disclosed |
| EP-3878465-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | Novartis AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-11091806-B2 | Genetic markers associated with response to CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-107849041-B | Genetic markers associated with response to CRTH2 receptor antagonists | 默沙东公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11034681-B2 | Crystal form of indole derivative and preparation method and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | 2021-06-15 | — | — | US | disclosed |
| CN-108137503-B | Process for the preparation of 1- (4-methanesulfonyl-2-trifluoromethyl-benzyl) -2-methyl-1H-pyrrolo [2,3-B ] pyridin-3-yl-acetic acid | 诺华股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-108137503-B | Process for the preparation of 1- (4-methanesulfonyl-2-trifluoromethyl-benzyl) -2-methyl-1H-pyrrolo [2,3-B ] pyridin-3-yl-acetic acid | 诺华股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-108484595-B | Simple synthesis method of asthma medicine Fevipiprant | 天津科技大学 | 2021-03-30 | — | — | CN | disclosed |
| US-10851165-B2 | Antibody molecules to PD-L1 and methods of treating cancer | NOVARTIS AG (CH) | 2020-12-01 | — | — | US | disclosed |
| EP-3741754-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020226936-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200347040-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS PHARMA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| EP-3356329-B1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3356329-B1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3356329-B1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3606924-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3606924-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3606924-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| CN-110759906-A | Prodrug of Fevipiprant and preparation method and application thereof | 重庆美普蓝科技有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | NOVARTIS AG (CH) | 2019-12-17 | — | — | US | disclosed |
| US-20190290225-A1 | AIRWAY MUCUS IMPACTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-09-26 | — | — | US | disclosed |
| WO-2019130166-A1 | PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID | MANKIND PHARMA LTD. (IN) | 2019-07-04 | — | — | WO | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489233-A1 | INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| WO-2019018640-A1 | DOSAGE REGIMENS FOR ANTI-GITR ANTIBODIES AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | WO | disclosed |
| US-20180371093-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | BILIC SANELA (US) | 2018-12-27 | — | — | US | disclosed |
| EP-3389712-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | Novartis AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| WO-2018178926-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018178926-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2018-10-04 | — | — | WO | disclosed |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2018-09-27 | — | — | US | disclosed |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS PHARMA AG (CH) | 2018-09-27 | — | — | US | disclosed |
| CN-108484595-A | A kind of succinct synthetic method of asthmatic medicament Fevipiprant | 天津科技大学 | 2018-09-04 | — | — | CN | disclosed |
| US-20180237856-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180222982-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | COSTIM PHARMACEUTICALS INC. | 2018-08-09 | — | — | US | disclosed |
| EP-3356329-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356329-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356329-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-20180186882-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | COSTIM PHARMACEUTICALS INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3337803-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3328418-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9988452-B2 | Antibody molecules to PD-L1 and uses thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| EP-3316902-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | Novartis AG (CH) | 2018-05-09 | — | — | EP | disclosed |
| WO-2017209272-A1 | CANCER METASTASIS INHIBITOR | 国立大学法人東京大学 | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210261-A1 | DEUTERATED FEVIPIPRANT | CONCERT PHARMACEUTICALS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170306038-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| EP-3206711-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | Novartis AG (CH) | 2017-08-23 | — | — | EP | disclosed |
| EP-3204419-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | Novartis AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017106656-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017104728-A1 | MEDICINE FOR TREATING FOOD ALLERGY | 国立大学法人東京大学 | 2017-06-22 | — | — | WO | disclosed |
| WO-2017056001-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | NOVARTIS AG (CH) | 2017-04-06 | — | — | WO | disclosed |
| WO-2017019858-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019897-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019896-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | NOVARTIS AG (CH) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017015418-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016061142-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-21 | — | — | WO | disclosed |
| US-20160108123-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-21 | — | — | US | disclosed |
| WO-2016057841-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | NOVARTIS AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-9206217-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8470848-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-06-25 | — | — | US | disclosed |
| US-8455645-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| EP-1761529-B3 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100210610-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-19 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (28 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267518-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | PTGDR2 29/4885 |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | PTGDR2 29/4885 |
| US-20100210610-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | PTGDR2 1399/4885 |
| US-11034681-B2 | Crystal form of indole derivative and preparation method and use thereof | HRH1, HRH2, MC2R | PTGDR2 77/4885 |
| US-20200347040-A1 | CRYSTAL FORM OF INDOLE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | HRH1, HRH2, MC2R | PTGDR2 77/4885 |
| US-20250228844-A1 | SINGLE NUCLEOTIDE POLYMORPHIC ALLELES OF HUMAN DP-2 GENE FOR DETECTION OF SUSCEPTIBILITY TO HAIR GROWTH INHIBITION BY PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885 |
| US-20200031824-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | MMAB, PAH, CPS1 | PTGDR2 2091/4885 |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | PTGDR2 4560/4885 |
| US-20180222982-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | CD274, PDCD1, PDCD1LG2 | PTGDR2 3847/4885 |
| US-20180273530-A1 | PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID | MMAB, PAH, CPS1 | PTGDR2 2091/4885 |
| US-10800765-B2 | Indole derivative used as CRTH2 inhibitor | NR3C2, CRHR2, TPH2 | PTGDR2 97/4885 |
| US-20170306038-A1 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY | CD4, IL2RA, IL2 | PTGDR2 840/4885 |
| US-20100204225-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | PTGDR2 1399/4885 |
| US-20180186882-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | PTGDR2 4227/4885 |
| US-10723735-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | MMAB, PAH, CPS1 | PTGDR2 2091/4885 |
| US-20180371093-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | CD274, PDCD1, PDCD1LG2 | PTGDR2 4295/4885 |
| US-12201625-B2 | Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2 | PTGDR2, PTGS2, HPGDS | PTGDR2 1/4885 |
| US-10508110-B2 | Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid | MMAB, PAH, CPS1 | PTGDR2 2091/4885 |
| US-10851165-B2 | Antibody molecules to PD-L1 and methods of treating cancer | CD274, PDCD1LG2, PDCD1 | PTGDR2 3618/4885 |
| US-20160108123-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | PTGDR2 4227/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | PTGDR2 4560/4885 |
| US-20180237856-A1 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | CRHR2, CRHR1, HRH2 | PTGDR2 18/4885 |
| US-20210284737-A1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | PTGDR2 4227/4885 |
| US-11091806-B2 | Genetic markers associated with response to CRTH2 receptor antagonists | CRHR2, CRHR1, HRH2 | PTGDR2 18/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PTGDR2 1724/4885 |
| US-20190290225-A1 | AIRWAY MUCUS IMPACTION | MUC1, IL5, CYSLTR2 | PTGDR2 77/4885 |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | CD274, PDCD1LG2, PDCD1 | PTGDR2 624/4885 |
| US-20220259656-A1 | BLOOD BIOMARKER AND GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CRTH2 RECEPTOR ANTAGONISTS | HRH2, HRH1, CRHR2 | PTGDR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.